The global human embryonic stem cells market is estimated to be USD 2.26 billion in 2024 and is expected to reach USD 6.76 billion by 2035, with a CAGR of 10.47% during the forecast period 2025-2035. The market will grow due to factors such as the growing prevalence of chronic diseases, advances in stem cell research, government funding and support, the growing need for regenerative medicine, and the increased emphasis on personalized medicine.
Recent advancements in stem cell research are propelling the field forward at an unprecedented pace. Notably, researchers at Rockefeller University have made significant strides in understanding early embryonic development by replicating the gastrulation phase using human embryonic stem cells. This groundbreaking study, published in ScienceDaily in March 2024, offers valuable insights into the genetic and molecular factors that govern cell fate decisions during this critical period. Such knowledge can potentially revolutionize our understanding of early developmental diseases and birth defects, paving the way for innovative therapeutic approaches.
By cell line type, the research-grade hESCs segment accounted for the largest revenue-grossing segment in the global human embryonic stem cells market in 2024 owing to the increasing use of these cell lines in preclinical studies, drug discovery, and disease modeling across academic and industrial research settings. For instance, the government of Abu Dhabi authorized projects in September 2023 to use human tissues and stem cells to further individualized medical research. Through the use of human stem cells and tissues for research, this project creates a biobank to enable the provision of individualized medical care through advanced treatment regimens. Additionally, the clinical-grade hESCs segment is predicted to grow at the fastest CAGR due to its rising application in regenerative therapies, clinical trials, and cell-based therapeutic interventions for chronic and degenerative diseases.
By application, the regenerative medicine segment accounted for the highest revenue-grossing segment in the global human embryonic stem cells market in 2024 owing to the growing adoption of hESC-derived therapies for treating conditions such as neurodegenerative diseases, cardiovascular disorders, and spinal cord injuries. For instance, the Biologics License Application (BLA) for StemCyte Inc.'s HPC, Cord Blood product REGENECYTETM, a vital cord blood stem cell therapy for transplantation in patients with blood and immune system disorders, was approved by the FDA in November 2024. A fully-owned subsidiary of StemCyte International Ltd. is StemCyte Inc. Additionally, the stem cell biology research segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on understanding cellular differentiation, disease mechanisms, and potential therapeutic targets through hESC-based research.
By end-user, the research institutes segment accounted for the highest revenue-grossing segment in the global human embryonic stem cells market in 2024 owing to the high levels of funding and government support for academic research into stem cell applications and fundamental biology. For instance, STEMCELL Technologies announced in January 2024 that it will acquire Propagenix Inc. The growth trajectory of Stemcell is significantly impacted by this purchase. It is anticipated that the merger will accelerate scientific research in labs and clinical settings to address a variety of ailments. Additionally, the biotechnology and pharmaceutical companies segment is predicted to grow at the fastest CAGR during the forecast period owing to its expanding role in developing commercial applications of hESCs for drug testing, personalized medicine, and cell-based therapies.
The North American region is anticipated to have the highest revenue share during the forecast period owing to its advanced healthcare infrastructure, significant investments in stem cell research, and strong regulatory framework supporting clinical trials and commercialization of human embryonic stem cell-based therapies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biotechnology sector, increasing government and private funding for stem cell research, and rising demand for regenerative medicine and drug discovery applications in countries like China, Japan, and India. For instance, Garuda Therapeutics said in February 2023 that, fifteen months after its first debut, it had raised an additional USD 62 million, totaling USD 72 million. The company increased the number of potential diseases it targeted from 70 to 120 and concentrated on creating stem cell-based medicines for a variety of illnesses.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Recent advancements in stem cell research are propelling the field forward at an unprecedented pace. Notably, researchers at Rockefeller University have made significant strides in understanding early embryonic development by replicating the gastrulation phase using human embryonic stem cells. This groundbreaking study, published in ScienceDaily in March 2024, offers valuable insights into the genetic and molecular factors that govern cell fate decisions during this critical period. Such knowledge can potentially revolutionize our understanding of early developmental diseases and birth defects, paving the way for innovative therapeutic approaches.
By cell line type, the research-grade hESCs segment accounted for the largest revenue-grossing segment in the global human embryonic stem cells market in 2024 owing to the increasing use of these cell lines in preclinical studies, drug discovery, and disease modeling across academic and industrial research settings. For instance, the government of Abu Dhabi authorized projects in September 2023 to use human tissues and stem cells to further individualized medical research. Through the use of human stem cells and tissues for research, this project creates a biobank to enable the provision of individualized medical care through advanced treatment regimens. Additionally, the clinical-grade hESCs segment is predicted to grow at the fastest CAGR due to its rising application in regenerative therapies, clinical trials, and cell-based therapeutic interventions for chronic and degenerative diseases.
By application, the regenerative medicine segment accounted for the highest revenue-grossing segment in the global human embryonic stem cells market in 2024 owing to the growing adoption of hESC-derived therapies for treating conditions such as neurodegenerative diseases, cardiovascular disorders, and spinal cord injuries. For instance, the Biologics License Application (BLA) for StemCyte Inc.'s HPC, Cord Blood product REGENECYTETM, a vital cord blood stem cell therapy for transplantation in patients with blood and immune system disorders, was approved by the FDA in November 2024. A fully-owned subsidiary of StemCyte International Ltd. is StemCyte Inc. Additionally, the stem cell biology research segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on understanding cellular differentiation, disease mechanisms, and potential therapeutic targets through hESC-based research.
By end-user, the research institutes segment accounted for the highest revenue-grossing segment in the global human embryonic stem cells market in 2024 owing to the high levels of funding and government support for academic research into stem cell applications and fundamental biology. For instance, STEMCELL Technologies announced in January 2024 that it will acquire Propagenix Inc. The growth trajectory of Stemcell is significantly impacted by this purchase. It is anticipated that the merger will accelerate scientific research in labs and clinical settings to address a variety of ailments. Additionally, the biotechnology and pharmaceutical companies segment is predicted to grow at the fastest CAGR during the forecast period owing to its expanding role in developing commercial applications of hESCs for drug testing, personalized medicine, and cell-based therapies.
The North American region is anticipated to have the highest revenue share during the forecast period owing to its advanced healthcare infrastructure, significant investments in stem cell research, and strong regulatory framework supporting clinical trials and commercialization of human embryonic stem cell-based therapies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biotechnology sector, increasing government and private funding for stem cell research, and rising demand for regenerative medicine and drug discovery applications in countries like China, Japan, and India. For instance, Garuda Therapeutics said in February 2023 that, fifteen months after its first debut, it had raised an additional USD 62 million, totaling USD 72 million. The company increased the number of potential diseases it targeted from 70 to 120 and concentrated on creating stem cell-based medicines for a variety of illnesses.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Report Scope:
- Base Year: 2024
- Forecast Period: 2025-2035
- Study Coverage
- Market Forecast by Cell Line Type, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Human Embryonic Stem Cells Market Report 2024 - 2035
Human Embryonic Stem Cells Market Analysis & Forecast by Cell Line Type 2024 - 2035 (Revenue USD Bn)
- Research-grade hESCs
- Clinical-grade hESCs
Human Embryonic Stem Cells Market Analysis & Forecast by Application 2024 - 2035 (Revenue USD Bn)
- Regenerative Medicine
- Stem Cell Biology Research
- Tissue Engineering
- Toxicology Testing
Human Embryonic Stem Cells Market Analysis & Forecast by End-User 2024 - 2035 (Revenue USD Bn)
- Research Institutes
- Biotechnology and Pharmaceutical Companies
- Hospitals and Specialty Clinics
Human Embryonic Stem Cells Market Analysis & Forecast by Region 2024 - 2035 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Human Embryonic Stem Cells Market: Cell Line Type Estimates & Trend Analysis
8. Human Embryonic Stem Cells Market: Application Estimates & Trend Analysis
9. Human Embryonic Stem Cells Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Human Embryonic Stem Cells Market
12. Europe Global Human Embryonic Stem Cells Market
13. Asia Pacific Global Human Embryonic Stem Cells Market
14. Latin America Global Human Embryonic Stem Cells Market
15. MEA Global Human Embryonic Stem Cells Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific
- STEMCELL Technologies
- Astellas Pharma
- ViaCyte
- OCATA Therapeutics (now part of Astellas)
- CellStemCell
- Cynata Therapeutics
- StemCells, Inc.
- International Stem Cell Corporation
- Biosplice Therapeutics
- ReNeuron
- Bluebird Bio
- GSK (GlaxoSmithKline)
- Stryker Corporation
- Garuda Therapeutics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.26 Billion |
| Forecasted Market Value ( USD | $ 6.76 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
